Document Type : Original Article


Smt. Sarojini Ramulamma College of Pharmacy, Seshadrinagar, Mahabubnagar, Telangana 509001, India


Cirrhosis is a late-stage liver disease in which/ advanced stage of scaring and conditions, such as hepatitis and chronic alcoholism. This disease is a condition in which your liver is scarred and permanently damaged. Scar tissue replaces healthy liver tissue and prevents your liver from working normally. Irreversible change in the normal liver tissue results in the degeneration of functioning liver cells and their replacement with fibrous connective tissue. In the present study, the risk assessment in alcoholic patients is assessed using laboratory data. Other biochemical parameters and severity are assessed using the child-pugh score. In the present study, 98 patients were identified of which 8 patients were excluded due to various reasons, and 90 patients’ data were analyzed. In order to assess the risk of cirrhosis in alcoholic patients, we used the cpugh score for assessing the severity and survival rate of subjects. A total of 90 patients were enrolled in this observational study. The study confirmed that more than 60 % of the subjects possess a severe risk of cirrhosis and risk factors such as age, gender, ALD, high BMI, social history family history, and encephalopathy.

Graphical Abstract

A retrospective observational study to assess the cirrhosis risk in alcoholic patients


Main Subjects

Selected author of this article by journal

Dr. Paspula Soumya
Sarojini Ramulamma College of Pharmacy


Open Access

This article is licensed under a CC BY License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit:


Publisher’s Note

CMBR journal remains neutral with regard to jurisdictional claims in published maps and institutional afflictions.


Letters to Editor

Given that CMBR Journal's policy in accepting articles will be strict and will do its best to ensure that in addition to having the highest quality published articles, the published articles should have the least similarity (maximum 15%). Also, all the figures and tables in the article must be original and the copyright permission of images must be prepared by authors. However, some articles may have flaws and have passed the journal filter, which dear authors may find fault with. Therefore, the editor of the journal asks the authors, if they see an error in the published articles of the journal, to email the article information along with the documents to the journal office.

CMBR Journal welcomes letters to the editor ([email protected], [email protected]) for the post-publication discussions and corrections which allows debate post publication on its site, through the Letters to Editor. Critical letters can be sent to the journal editor as soon as the article is online. Following points are to be considering before sending the letters (comments) to the editor.

[1] Letters that include statements of statistics, facts, research, or theories should include appropriate references, although more than three are discouraged.

[2] Letters that are personal attacks on an author rather than thoughtful criticism of the author’s ideas will not be considered for publication.

[3] There is no limit to the number of words in a letter.

[4] Letter writers should include a statement at the beginning of the letter stating that it is being submitted either for publication or not.

[5] Anonymous letters will not be considered.

[6] Letter writers must include Name, Email Address, Affiliation, mobile phone number, and Comments.

[7] Letters will be answered as soon as possible.

  1. Julien J, Ayer T, Bethea ED, Tapper EB, Chhatwal J (2020) Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019–40: a modelling study. The Lancet Public Health 5(6):e316-e323. doi:
  2. Bogliotti Y, Vander Roest M, Mattis AN, Gish RG, Peltz G, Anwyl R, Kivlighn S, Schuur ER (2022) Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review. Cells 11(13):1998. doi:
  3. Fatullayeva S, Tagiyev D, Zeynalov N (2021) A review on enterosorbents and their application in clinical practice: Removal of toxic metals. Colloid and Interface Science Communications 45:100545. doi:
  4. Martínez-Leal J, Ponce-García N, Escalante-Aburto A (2020) Recent Evidence of the Beneficial Effects Associated with Glucuronic Acid Contained in Kombucha Beverages. Current Nutrition Reports 9(3):163-170. doi:
  5. Zen Y, Yeh MM (2019) Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy. Seminars in Diagnostic Pathology 36(6):434-440. doi:
  6. Bernsmeier C, van der Merwe S, Périanin A (2020) Innate immune cells in cirrhosis. Journal of Hepatology 73(1):186-201. doi:
  7. Trebicka J, Bork P, Krag A, Arumugam M (2021) Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nature Reviews Gastroenterology & Hepatology 18(3):167-180. doi:
  8. Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C (2021) Non-alcoholic fatty liver disease: A patient guideline. JHEP Reports 3(5):100322. doi:
  9. Valenzuela-Vallejo L, Mantzoros CS (2022) Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD). Metabolism 134:155246. doi:
  10. Neshat SY, Quiroz VM, Wang Y, Tamayo S, Doloff JC (2021) Liver Disease: Induction, Progression, Immunological Mechanisms, and Therapeutic Interventions. International Journal of Molecular Sciences 22(13):6777. doi:
  11. Li H (2021) Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Review of Gastroenterology & Hepatology 15(3):217-233. doi:
  12. Kadiri DD, Peela S, Ganguli D (2022) Chapter 4 - Effect of cirrhosis and hepatitis on the prognosis of liver cancer. In: Nagaraju GP, Peela S (eds) Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma. Academic Press, pp 51-72. doi:
  13. Mishra D, Dash KR, Khatua C, Panigrahi S, Parida PK, Behera SK, Barik RK, Pradhan S, Sahu SK, Thakur B, Singh SP (2020) A Study on the Temporal Trends in the Etiology of Cirrhosis of Liver in Coastal Eastern Odisha. Euroasian journal of hepato-gastroenterology 10(1):1-6. doi:
  14. Ali FAZ, Abdel-Maksoud FM, Abd Elaziz HO, Al-Brakati A, Elmahallawy EK (2021) Descriptive Histopathological and Ultrastructural Study of Hepatocellular Alterations Induced by Aflatoxin B1 in Rats. Animals 11(2):509. doi:
  15. Khan S, Saxena R (2021) Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review. Advances in anatomic pathology 28(6):408-414. doi:
  16. Gracia-Sancho J, Manicardi N, Ortega-Ribera M, Maeso-Díaz R, Guixé-Muntet S, Fernández-Iglesias A, Hide D, García-Calderó H, Boyer-Díaz Z, Contreras PC, Spada A, Bosch J (2019) Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism. Hepatology Communications 3(7):987-1000. doi:
  17. Premkumar M, Anand AC (2022) Overview of Complications in Cirrhosis. Journal of Clinical and Experimental Hepatology 12(4):1150-1174. doi:
  18. Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, Chalasani N (2020) Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. Hepatology 71(2):495-509. doi:
  19. Costa M, Barré T, Antwerpes S, Coste M, Bureau M, Ramier C, Maradan G, Riccobono-Soulier O, Vassas-Goyard S, Casanova D, Carrieri P (2022) A Community-Based Therapeutic Education Programme for People with Alcohol Use Disorder in France: A Qualitative Study (ETHER). International Journal of Environmental Research and Public Health 19(15):9228. doi:
  20. Hajifathalian K, Torabi Sagvand B, McCullough AJ (2019) Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study. Hepatology 70(2):511-521. doi:
  21. Kanwal F, Kramer JR, Li L, Dai J, Natarajan Y, Yu X, Asch SM, El-Serag HB (2020) Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology 71(3):808-819. doi:
  22. Gustot T, Jalan R (2019) Acute-on-chronic liver failure in patients with alcohol-related liver disease. Journal of Hepatology 70(2):319-327. doi:
  23. Hernaez R, Liu Y, Kramer JR, Rana A, El-Serag HB, Kanwal F (2020) Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. Journal of Hepatology 73(6):1425-1433. doi:
  24. Zhang Y, Huang C, Nie Y, Liu Q, Xiao N, Liu L, Zhu X (2021) Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis. Frontiers in Medicine 8. doi:
  25. Rehm J, Shield KD (2019) Global Burden of Alcohol Use Disorders and Alcohol Liver Disease. Biomedicines 7(4):99. doi:
  26. Önnerhag K, Hartman H, Nilsson PM, Lindgren S (2019) Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). Scandinavian Journal of Gastroenterology 54(3):328-334. doi:
  27. Nier A, Brandt A, Conzelmann IB, Özel Y, Bergheim I (2018) Non-Alcoholic Fatty Liver Disease in Overweight Children: Role of Fructose Intake and Dietary Pattern. Nutrients 10(9):1329. doi:
  28. Mass Sanchez PB, Krizanac M, Weiskirchen R, Asimakopoulos A (2021) Understanding the Role of Perilipin 5 in Non-Alcoholic Fatty Liver Disease and Its Role in Hepatocellular Carcinoma: A Review of Novel Insights. International Journal of Molecular Sciences 22(10):5284. doi:
  29. Liu X, Xie W, Meng S, Kang X, Liu Y, Guo L, Wang C (2022) Small Nucleolar RNAs and Their Comprehensive Biological Functions in Hepatocellular Carcinoma. Cells 11(17):2654. doi:
  30. Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M (2019) Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. International Journal of Molecular Sciences 20(6):1358. doi:
  31. Zhang C-h, Cheng Y, Zhang S, Fan J, Gao Q (2022) Changing epidemiology of hepatocellular carcinoma in Asia. Liver International 42(9):2029-2041. doi:
  32. Isaia I, Natoli G, Colaci M, Stancanelli B, Malatino L (2022) Sclerosing cholangitis may mimic radiological pattern of cholangiocarcinoma: Differential diagnosis and review of literature. The American Journal of the Medical Sciences 364(3):359-365. doi:
  33. Vintilă A-M, Horumbă M, Vintilă VD (2020) History and Physical Examination. In: Radu-Ionita F, Pyrsopoulos NT, Jinga M, Tintoiu IC, Sun Z, Bontas E (eds) Liver Diseases: A Multidisciplinary Textbook. Springer International Publishing, Cham, pp 397-406. doi:
  34. Wong GL-H, Wong VW-S, Thompson A, Jia J, Hou J, Lesmana CRA, Susilo A, Tanaka Y, Chan W-K, Gane E, Ong-Go AK, Lim S-G, Ahn SH, Yu M-L, Piratvisuth T, Chan HL-Y (2020) Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. The Lancet Gastroenterology & Hepatology 5(8):776-787. doi:
  35. Elbahrawy A, Ibrahim MK, Eliwa A, Alboraie M, Madian A, Aly HH (2021) Current situation of viral hepatitis in Egypt. Microbiology and Immunology 65(9):352-372. doi:
  36. Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B (2020) Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLOS Medicine 17(4):e1003100. doi:
  37. Kezer CA, Simonetto DA, Shah VH (2021) Sex Differences in Alcohol Consumption and Alcohol-Associated Liver Disease. Mayo Clinic Proceedings 96(4):1006-1016. doi:
  38. Bajaj JS, Gentili A, Wade JB, Godschalk M (2022) Specific Challenges in Geriatric Cirrhosis and Hepatic Encephalopathy. Clinical Gastroenterology and Hepatology 20(8, Supplement):S20-S29. doi:
  39. Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, Perumalswami P, Roytman M, Li M, Vogel AS, Catana AM, Wegermann K, Carr RM, Aloman C, Chen VL, Rabiee A, Sadowski B, Nguyen V, Dunn W, Chavin KD, Zhou K, Lizaola-Mayo B, Moghe A, Debes J, Lee T-H, Branch AD, Viveiros K, Chan W, Chascsa DM, Kwo P, Dhanasekaran R (2021) Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. Clinical Gastroenterology and Hepatology 19(7):1469-1479.e1419. doi:
  40. Fujiyama S, Akuta N, Sezaki H, Kobayashi M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H (2021) Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study. BMC Gastroenterology 21(1):189. doi:
  41. Zhou Q-H, Hu C-Q, Shi Y, Wu F-T, Yang Q, Guan J, Li A-C, Chen Z (2021) Cryptococcosis in patients with liver cirrhosis: Death risk factors and predictive value of prognostic models. Hepatobiliary & Pancreatic Diseases International 20(5):460-468. doi: